| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
EXTENDED REPORT |
1 René Descartes University, Cochin Hospital, Rheumatology B Department, Paris, France
2 University Hospital Maastricht, Maastricht, The Netherlands
3 Merck Research Laboratories, Rahway, NJ, USA
Correspondence to:
Correspondence to:
Dr L Gossec
Hôpital Cochin, Rhumatologie B, Paris, France; laure.gossec{at}cch.aphp.fr
Objective: The combined efficacy of selective and non-selective cyclo-oxygenase-2 (COX-2) inhibition on the axial manifestations of ankylosing spondylitis (AS) in the presence or absence of chronic peripheral arthritis was evaluated.
Methods: In a post hoc subgroup analysis of a 6 week, randomised, double blind, placebo controlled trial, 387 patients with active axial AS were randomised to receive etoricoxib 90 mg or 120 mg once a day, naproxen 500 mg twice daily, or placebo. Randomisation was stratified by the presence or absence of chronic peripheral arthritis. The primary outcome measure was the time weighted average change from baseline of spine pain intensity. Efficacy data from the three groups receiving active treatment (the NSAID/COX-2 inhibitor group) were combined to improve precision. An analysis of covariance model was used to evaluate the effect of peripheral disease on treatment response.
Results: 93 patients were allocated to receive placebo and 294 to active treatment (naproxen or etoricoxib). The combined NSAID/COX-2 inhibitor group had a significant treatment response compared with the placebo group for all efficacy measures, both in patients with and without peripheral arthritis. A significantly greater difference in mean patient assessment of spine pain was found between active and placebo treatments in patients without compared with those with peripheral arthritis (p = 0.005; –32.5 mm v –17.0 mm, respectively). Similar differences, although not statistically significant, were seen for other end points.
Conclusion: NSAIDs and COX-2 inhibitors have a clinically relevant symptomatic effect on axial AS irrespective of the presence of peripheral arthritis. In this exploratory analysis spinal improvement appeared to be greater in patients without peripheral disease.
Abbreviations: ANCOVA, analysis of covariance; AS, ankylosing spondylitis; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; CI, confidence interval; COX-2, cyclo-oxygenase-2; DMARDs, disease modifying antirheumatic drugs; NSAIDs, non-steroidal anti-inflammatory drugs; VAS, visual analogue scale
Keywords: ankylosing spondylitis; non-steroidal anti-inflammatory drugs; efficacy; peripheral arthritis; etoricoxib
This article has been cited by other articles:
|
|
 |
|
  P. I. Sidiropoulos, G. Hatemi, I.-H. Song, J. Avouac, E. Collantes, V. Hamuryudan, M. Herold, T. K. Kvien, H. Mielants, J. M. Mendoza, et al. Evidence-based recommendations for the management of ankylosing spondylitis: systematic literature search of the 3E Initiative in Rheumatology involving a broad panel of experts and practising rheumatologists Rheumatology, March 1, 2008; 47(3): 355 - 361. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Sieper, T Klopsch, M Richter, A Kapelle, M Rudwaleit, S Schwank, E Regourd, and M May Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study Ann Rheum Dis, March 1, 2008; 67(3): 323 - 329. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J Zochling, D van der Heijde, M Dougados, and J Braun Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis Ann Rheum Dis, April 1, 2006; 65(4): 423 - 432. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
